Transcutaneous Auricular Vagus Nerve Stimulation Device in CKD Population - Trial NCT05981183
Access comprehensive clinical trial information for NCT05981183 through Pure Global AI's free database. This phase not specified trial is sponsored by NYU Langone Health and is currently Recruiting. The study focuses on Chronic Kidney Disease. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
NYU Langone Health
Timeline & Enrollment
N/A
Aug 07, 2023
Aug 07, 2025
Primary Outcome
Heart Rate Variability (HRV) at Baseline,HRV at Post-Intervention
Summary
The purpose of this pilot interventional study is to collect preliminary data on the
 application of a transcutaneous auricular vagal nerve stimulation (taVNS) device in patients
 with chronic kidney disease (CKD). This data will enhance understanding of the short-term
 safety, tolerability and effects of this novel therapeutic approach in the setting of CKD.
 The primary aims are to investigate the feasibility of the protocol and generate preliminary
 signals of efficacy and tolerability for two different doses of vagal nerve stimulation. The
 pilot estimates will be used to design a larger scale study that may lead to potentially
 targeted interventions to reduce cardiovascular (CV) mortality in the CKD population.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05981183
Device Trial